Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation
Launched by SANOFI · Apr 20, 2007
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Smokers smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit
- • Motivated to quit with a score greater than or equal to 6 on the ten-point Motivation Scale
- Exclusion Criteria:
- • Non tobacco cigarettes consumption
- • Chronic use of marijuana
- • Pregnancy, breastfeeding
- • Any clinically significant disease that might interfere with the efficacy or safety evaluation of the study drug
- • Concomitant use of drugs as an aid to smoking cessation or that might induce weight change
About Sanofi
Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bridgewater, New Jersey, United States
Patients applied
Trial Officials
Clinical Sciences & Operations
Study Director
Sanofi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials